GBT’s Oxbryta (voxelotor) Receives CHMP Positive Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease
Shots:
- The EMA’s CHMP has adopted a positive opinion recommending the marketing authorization for Oxbryta to treat hemolytic anemia due to SCD in patients aged ≥12yrs. as monothx or in combination with hydroxycarbamide
- The CHMP opinion is based on the P-III (HOPE) study of Oxbryta vs PBO in 274 patients aged ≥12yrs. with SCD which showed that patients achieved a 1 g/dL increase in Hb (51.1% vs 6.5%) @24wks., improvements in markers of hemolysis in indirect bilirubin & reticulocyte percentage & a favorable safety profile
- If approved by the EC, Oxbryta will receive marketing authorization in all EU member states, Iceland, Liechtenstein & Norway with an expected EC’s decision in Q1’22
Ref: Globe Newswire | Image: GBT
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com